Acknowledgements
Athanas, TMP-IL, Cancer
ONCOLOGY, CANCER
This study was sponsored by Mirati Therapeutics, Inc. Medical writing support under the direction of the authors was provided by Charlotte Kennerley, PhD, of Ashfield MedComms, an Ashfield Health company, and funded by Mirati Therapeutics, Inc. The study was designed by the academic authors and the sponsor (Mirati Therapeutics, Inc.). Data were collected by the academic authors and their research teams and were interpreted by the authors and the sponsor. The corresponding authors had full access to the data in the study and had final responsibility for the decision to submit for publication. The authors would like to acknowledge Alice Chu, Mirati Therapeutics Inc, for statistical support; Yong Liu, Mirati Therapeutics Inc, for support with the PK data interpretation; Lisa Vuchak, Mirati Therapeutics for Medical Affairs support, and Argus Athanas and Laura Hover of Monoceros Biosystems for data analysis and bioinformatics support. P.M. is supported by a Career Development Award by the American Society of Clinical Oncology, a Research Award by KCCure, the MD Anderson Khalifa Scholar Award, the MD Anderson Physician-Scientist Award, philanthropic donations by Mike and Mary Allen, and the Andrew Sabin Family Foundation Fellowship. This study was supported by the NIH CCSG Award (CA016672 (Institutional Tissue Bank (ITB) and Research Histology Core Laboratory (RHCL)), Adaptive Patient-Oriented Longitudinal Learning and Optimization (APOLLO) Moonshot Program, Strategic Alliances and the Translational Molecular Pathology-Immunoprofiling Lab (TMP-IL) at the Department Translational Molecular Pathology, the University of Texas MD Anderson Cancer Center.